Arbutus Biopharma (ABUS) Reports FY18 Loss of $1.21

Arbutus Biopharma (NASDAQ: ABUS) reported FY18 EPS of ($1.21), versus ($1.56) reported last year. Revenue for the year came in at $5.9 million, versus $10.7 million reported last year.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c